Micafungin Biocon (Micafungin)

Micafungin blocks the enzyme β‑(1,3)‑D‑glucan synthase, preventing the synthesis of β‑(1,3)‑D‑glucan, an essential structural polysaccharide of the fungal cell wall. Without this component, the cell wall becomes weak, leading to osmotic lysis and fungal cell death while sparing human cells that lack this pathway.

The specific dosage of Micafungin Biocon is determined by the prescribing clinician based on the patient’s infection type, severity, weight, renal and hepatic function, and other clinical factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes.

Safety data for Micafungin in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss uncertainties and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Micafungin belongs to the echinocandin class, which inhibits fungal cell‑wall synthesis, whereas azoles target ergosterol synthesis and polyenes bind directly to membrane sterols. Echinocandins, including micafungin, are often preferred for invasive Candida infections due to their fungicidal activity and lower drug‑interaction potential.

Micafungin Biocon should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability until it is prepared for intravenous infusion.

Micafungin Biocon is given by intravenous infusion, typically over a period of 1 hour. The infusion rate and duration are set by the healthcare provider, who monitors the patient for any infusion‑related reactions during and after administration.

Serious risks include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, and infusion‑related events like hypotension or respiratory distress. Patients should be monitored for liver enzyme elevations and any signs of allergic response throughout treatment.

Micafungin Biocon is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver disease, and it should be avoided in those receiving strong CYP3A4 inducers without close monitoring.